- 1、本文档共79页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:肾癌靶向治疗_省肿瘤大会.ppt
* CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. ? The main result for this trial was a survival advantage for patients randomized to everolimus: a median progression-free survival time of 4 months compared with 2 months for patients randomized to placebo. HR, hazard ratio; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center. ? This forest plot shows a subset analysis for various subsets in this particular trial. It shows no meaningful difference across subsets whether looking at MSKCC risk, type of previous treatment, age, sex, or geographic region. * IFN, interferon; Neph, nephrectomy; OS, overall survival. ? This was a combined analysis from 2 large phase?III trials that randomized more than 300?patients with metastatic renal cell carcinoma (RCC) to either nephrectomy or no nephrectomy followed by interferon?alfa for all patients. The median overall survival in patients who underwent upfront nephrectomy was nearly 6 months longer (P = .001). These data (which are from trials that accrued in the 1990s) resulted in debulking nephrectomy becoming a standard of care for patients who presented with metastatic kidney cancer. * * CI, confidence interval; mRCC, metastatic renal cell carcinoma; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease. ? Other single?arm phase?II trials in the setting of refractory RCC are evaluating these novel agents. This multicenter, single?arm, phase?II trial examined sunitinib in patients who had received previous bevacizumab?based treatment. A partial response rate of 23% was noted, with approximately 75% of patients experiencing some form of tumor burden reduction. Compared with sunitinib in untreated patients, the objective response rate is approximately one half, but the number of patients with reduced tumor burden is similar. IFN, interferon; Neph
您可能关注的文档
- 课件:疾病的单基因遗传.ppt
- 课件:泌尿系统疾病影像诊断与技术.ppt
- 课件:根本死亡原因判定解析.ppt
- 课件:呼吸系统心身疾病.ppt
- 课件:过敏性紫癜概述.ppt
- 课件:免疫学技术.ppt
- 课件:十二指肠乳头癌.ppt
- 课件:骨与关节结核总结.ppt
- 课件:奶厅管理程序.ppt
- 课件:膏方在肺系疾病中的运用.ppt
- 《晶硅电池组件智造技术》课件——14.接线盒质量控制课件.pdf
- 《晶硅电池组件智造技术》课件——41.组件固化工艺.pdf
- 《建筑装饰工程信息管理》课件——建设工程文件档案资料管理职责.pptx
- 《建筑装饰工程计量与计价》课件——基本建设预算分类和作用.pptx
- 《晶硅电池组件智造技术》课件——13.铝型材质量控制课件.pdf
- 《晶硅电池组件智造技术》课件——36.后外观检和EL测试工艺课件.pdf
- 《晶硅电池组件智造技术》课件——12.光伏玻璃质量控制课件.pdf
- 《结构设计原理》课件——圆形截面偏心受压构件的正截面承载力计算-基本假定.pptx
- 《晶硅电池组件智造技术》课件——31.组件层压前返修工艺.pdf
- 《结构设计原理》课件——相对界限受压区高度.pptx
文档评论(0)